Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Heinzelmann, G. Preissler, H. Winter, R. Hatz, I. Koch, M. Lindner, J. Behr, O. Eickelberg (Munich, Gauting, Germany). Fibroblast heterogeneity in the diseased lung. Eur Respir J 2014; 44: Suppl. 58, 788

Member's Comments

No comment yet.

Related content which might interest you: The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Mucus production, lung inflammation and functional decay in IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Neuroendocrine cell hyperplasia (NEHI) and NEHI Syndrome: Lung biopsy necessary? Source: International Congress 2014 – ILDs 4 Year: 2014 Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 Interstitial lung disease in the connective tisssue disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Source: International Congress 2014 – IPF and surroundings Year: 2014 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Type V collagen induced pulmonary fibrosis in C57Bl/6mice Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014